- Mark M. SmithProfessor of Patholoy, Department of Pathology, 2103 Cornell Road, Cleveland, Ohio 44106 USAInterests: 174 peer-reviewed, 386 reviews and chapters publications, 6 active grants, Editor of Frontiers in Bioscience, International Journal of Experimental Pathology, Journal of Alzheimer\\\\\\\\\\\\\\\'s Disease, Neurochemistry International, Journal of Neuroscience Research, Redox Report, Free Radical Biology and Medicine, International Journal
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
Transition metal chelator therapy – a potential treatment for Alzheimer's disease?Anastazija Gnjec, Justin A Fonte, Craig Atwood, Ralph N. MartinsFront. Biosci. (Landmark Ed) 2002, 7(4), 1016–1023; https://doi.org/10.2741/gnjec7Download15Citations4Views
Significance of intracellular Aβ42 accumulation in Alzheimer's diseaseT Tabira, D H Chui, S KurodaFront. Biosci. (Landmark Ed) 2002, 7(1), 44–49; https://doi.org/10.2741/tabira7Download20Citations10Views
Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer β-amyloid peptide in vitro and in patientsJoseph D Buxbaum, Edward I Cullen, Lawrence T FriedhoffFront. Biosci. (Landmark Ed) 2002, 7(1), 50–59; https://doi.org/10.2741/A7395Download1Citations11Views